Neoplasms

3,817 trials 1,526 recruiting

Filter these 3,817 trials by phase, country and sponsor.

Open in Search →

Atezolizumab plus RP1 oncolytic immunotherapy in the NeoAdjuvant setting of Triple-Negative Breast Cancer Ended

2022-502311-12-00 Patients with early-stage Triple Negative Breast Cancer 4 2024-04-05
Regorafenib-pembrolizumab vs. TACE/TARE in intermediate-stage HCC beyond up-to-7. Ended

2022-501969-42-00 Intermediate-stage hepatocellular carcinoma with beyond 5 2024-03-28
A trial to learn how much [11C]savolitinib enters the brains of healthy participants Ended

2023-508334-34-00 Healthy Volunteers 3 2024-03-27
A Phase 2 Study of MK-4280A for the Treatment of Selected Solid Tumors Ended

2023-505022-34-00 Neoplasm malignant 4 2024-03-27
TACTIVE-U: An Umbrella Study to Investigate the Safety and Antitumor Activity of vepdegestrant (ARV-471) in Combination With Other Medicines… Ended

2023-507125-41-00 Advanced or Metastatic Breast Cancer 9 2024-03-25
FIH study of ALE.C04 anti-CLDN1 mAb monotherapy or in combination with pembrolizumab in patients with R/M HNSCC Ended

2023-505145-93-00 Recurrent or Metastatic (R/M) Head and Neck Squamous Ce 7 2024-03-21
A Study to Evaluate Safety and Preliminary Anti-tumor Activity of Debio 0123 as Monotherapy in Adult Participants With Advanced Solid Tumors Ended

2023-504824-24-00 Arm A: Diagnosed with uterine serous carcinoma (USC) Ar 3 2024-03-15
A PHASE II STUDY OF ADJUVANT ATEZOLIZUMAB OR ATEZOLIZUMAB PLUS TIRAGOLUMAB IN SOLID TUMORS WITH RESECTABLE DISEASE WITH INTERMEDIATE-HIGH RI… Ended

2024-512635-71-00 Solid tumors 4 2024-03-14
A Study of Tobemstomig/RO7247669 Combined with Nab-Paclitaxel Compared with Pembrolizumab Combined with Nab-Paclitaxel in Participants with … Ended

2022-502457-34-00 Triple-Negative Breast Cancer (TNBC) 4 2024-03-13
Phase II study evaluating Holmium-166 TARE followed by maIntenance Therapy in liver limited unresectable colorectal cancer patients after fi… Ended

2023-505356-22-00 Liver limited unresectable colorectal cancer 4 2024-03-13
A Trial to Investigate TransCon TLR7/8 Agonist in Combination with Pembrolizumab, TransCon TLR7/8 Agonist in Combination with TransCon IL-2 … Ended

2023-506092-10-00 Stage III-IVA Resectable Locoregionall Advanced Head an 4 2024-03-11
A trial to determine how nanatinostat is absorbed, modified, and removed from the body and the amount of nanatinostat that becomes available… Ended

2023-508184-74-00 Advanced cancer 3 2024-02-28
GEN1046 in Combination With Anticancer Agents for the Treatment of Advanced Endometrial Cancer Ended

2022-502453-33-00 Advanced Endometrial Cancer 4 2024-02-26
Tuvusertib (M1774) Human Mass Balance and Absolute Bioavailability Study (DDRIVER Solid Tumors 303) Ended

2022-502940-10-00 Advanced Solid Tumors 3 2024-02-23
A clinical study for patients with newly diagnosed, locally advanced non-small cell lung cancer (NSCLC) with a change in the ALK-gene, to te… Ended

2022-502467-38-00 Non-small cell lung cancer (NSCLC) 4 2024-02-22
A study to evaluate the Safety, Tolerability, Pharmacokinetics (PK), Pharmacodynamics (PD), and preliminary Anti-Tumor activity of RO7616789… Ended

2023-506354-20-00 Small Cell Lung Cancer and Neuroendocrine Carcinoma 1 2024-02-20
68Ga-FAPI PET/CT: The Diagnostic Accuracy for Primary Staging and Re-staging after Chemotherapy in Patients with Gastric and Gastro-Esophage… Ended

2023-505916-40-01 Gastroesophageal junction cancer (GEJ-cancer) 4 2024-02-15
Efficacy evaluation of 188Re-SSS lipiodol Selective Internal Radiation Therapy of non operable hepatocellular carcinoma patients, a phase II… Ended

2023-503341-60-00 non-operable hepatocellular carcinoma 4 2024-02-14
A Phase 1 Study of JNJ-79032421 Targeting Mesothelin for Advanced Stage Solid Tumors Ended

2023-504896-26-00 Advanced Stage Solid Tumors 1 2024-02-09
A Study to Learn If the Study Medicine Called Vepdegestrant Changes How the Body Processes the Other Study Medicine Called Midazolam Ended

2023-508518-40-00 ER+/HER2 positive breast cancer 3 2024-02-05
A Window-of-Opportunity study of hormone therapy in premenopausal women with ER-positive/HER2-negative early breast cancer. Ended

2022-503013-32-00 ER-positive/HER2-negative early breast cancer 4 2024-01-29
ADME: A Study to Understand What the Body does to the Study Compound Called PF-07220060 When Taken by Healthy Adults. Ended

2023-507074-40-00 metastatic/advanced breast cancer 3 2024-01-26
A study to learn how BAY2927088 is taken up and handled by the body in healthy male participants Ended

2022-502771-38-00 Advanced non-small cell lung cancer with EGFR and/or HE 3 2024-01-24
A Multicenter, Open-Label Clinical Trial of RVU120 in Patients with Relapsed or Refractory High-Risk Myelodysplastic Syndrome or Acute Myelo… Ended

2023-505910-10-00 Relapsed or Refractory High-Risk Myelodysplastic Syndro 4 2024-01-23